Trial Profile
Phase I, first-in-human Proof-of-Concept, randomized, double-blind study of VK0214 in X-Linked Adrenoleukodystrophy (X-ALD)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Aug 2021
Price :
$35
*
At a glance
- Drugs VK 0214 (Primary)
- Indications Adrenoleucodystrophy
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Viking Therapeutics
- 28 Jul 2021 According to a Viking Therapeutics media release, the study achieved both primary and secondary objectives.
- 28 Jul 2021 Status changed from recruiting to completed, according to a Viking Therapeutics media release.
- 17 Jun 2021 Results published in the Viking Therapeutics Media Release